Brind.

Ovid Therapeutics operates within the Biotechs industry.

1 report, 1 independent Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ovid Therapeutics operates within the Biotechs industry.

Who's involved

What this event is mainly about
Ovid Therapeutics (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Ovid Therapeutics' candidate OV329 targets GABA aminotransferase, amidst general FDA approval news for biotech stocks.Sub-event
  2. Ovid Therapeutics sold ganaxolone royalty rights to Immedica, which subsequently acquired Ovid's IP portfolio and completed the acquisition of Marinus.Sub-event
  3. Ovid Therapeutics operates in the biotechs industry.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations Explore Ovid Therapeutics's Fair Values from the Community and select yours Revenue: US$6.27m (up by US$6.10m from 2Q 2024). Net lo